366 related articles for article (PubMed ID: 29105562)
21. Medullary thyroid carcinoma with nodular goiter carries an excellent prognosis.
Xu L; Wang WB; Zhao YP; Zhang TP; Liao Q; Chen G; Zhou L; Shu H
J Surg Oncol; 2012 Aug; 106(2):169-73. PubMed ID: 22354558
[TBL] [Abstract][Full Text] [Related]
22. Metastatic lymph node ratio can further stratify risk for mortality in medullary thyroid cancer patients: A population-based analysis.
Qu N; Shi RL; Lu ZW; Liao T; Wen D; Sun GH; Li DS; Ji QH
Oncotarget; 2016 Oct; 7(40):65937-65945. PubMed ID: 27588396
[TBL] [Abstract][Full Text] [Related]
23. Survival implications of cervical lymphadenectomy in patients with medullary thyroid cancer.
Kandil E; Gilson MM; Alabbas HH; Tufaro AP; Dackiw A; Tufano RP
Ann Surg Oncol; 2011 Apr; 18(4):1028-34. PubMed ID: 21046269
[TBL] [Abstract][Full Text] [Related]
24. Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome.
Alzumaili B; Xu B; Spanheimer PM; Tuttle RM; Sherman E; Katabi N; Dogan S; Ganly I; Untch BR; Ghossein RA
Mod Pathol; 2020 Sep; 33(9):1690-1701. PubMed ID: 32313184
[TBL] [Abstract][Full Text] [Related]
25. Changing trends in the clinicopathological features and clinical outcomes of medullary thyroid carcinoma.
Kwon H; Kim WG; Sung TY; Jeon MJ; Song DE; Lee YM; Yoon JH; Chung KW; Hong SJ; Baek JH; Lee JH; Kim TY; Shong YK; Kim WB
J Surg Oncol; 2016 Feb; 113(2):152-8. PubMed ID: 26799259
[TBL] [Abstract][Full Text] [Related]
26. Long-term prognosis of medullary thyroid carcinoma.
Rendl G; Manzl M; Hitzl W; Sungler P; Pirich C
Clin Endocrinol (Oxf); 2008 Sep; 69(3):497-505. PubMed ID: 18331612
[TBL] [Abstract][Full Text] [Related]
27. CD133 Expression in Medullary Thyroid Cancer Cells Identifies Patients with Poor Prognosis.
Cordero-Barreal A; Caleiras E; López de Maturana E; Monteagudo M; Martínez-Montes ÁM; Letón R; Gil E; Álvarez-Escolá C; Regojo RM; Andía V; Marazuela M; Guadalix S; Calatayud M; Robles-Díaz L; Aguirre M; Cano JM; Díaz JÁ; Saavedra P; Lamas C; Azriel S; Sastre J; Aller J; Leandro-García LJ; Calsina B; Roldán-Romero JM; Santos M; Lanillos J; Cascón A; Rodríguez-Antona C; Robledo M; Montero-Conde C
J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32791518
[TBL] [Abstract][Full Text] [Related]
28. Long term prognosis of medullary thyroid carcinoma in 39 patients.
Voutilainen PE; Multanen M; Haapiainen RK; Haglund CH; Sane T; Sivula AH
Ann Chir Gynaecol; 2000; 89(4):292-7. PubMed ID: 11204961
[TBL] [Abstract][Full Text] [Related]
29. Sporadic medullary microcarcinoma of the thyroid: a retrospective analysis of eighty cases.
Beressi N; Campos JM; Beressi JP; Franc B; Niccoli-Sire P; Conte-Devolx B; Murat A; Caron P; Baldet L; Kraimps JL; Cohen R; Bigorgne JC; Chabre O; Lecomte P; Modigliani E
Thyroid; 1998 Nov; 8(11):1039-44. PubMed ID: 9848720
[TBL] [Abstract][Full Text] [Related]
30. Medullary thyroid carcinoma: multivariate analysis of prognostic factors influencing survival.
Peixoto Callejo I; Américo Brito J; Zagalo CM; Rosa Santos J
Clin Transl Oncol; 2006 Jun; 8(6):435-43. PubMed ID: 16790397
[TBL] [Abstract][Full Text] [Related]
31. Expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinase 2 (TIMP-2) in medullary thyroid carcinoma: prognostic implications.
Cavalheiro BG; Junqueira CR; Brandão LG
Thyroid; 2008 Aug; 18(8):865-71. PubMed ID: 18651826
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of lymph node yield and metastatic lymph node ratio in medullary thyroid carcinoma.
Leggett MD; Chen SL; Schneider PD; Martinez SR
Ann Surg Oncol; 2008 Sep; 15(9):2493-9. PubMed ID: 18594930
[TBL] [Abstract][Full Text] [Related]
33. Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma.
Gimm O; Ukkat J; Dralle H
World J Surg; 1998 Jun; 22(6):562-7; discussion 567-8. PubMed ID: 9597929
[TBL] [Abstract][Full Text] [Related]
34. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival.
Akslen LA; Varhaug JE
Cancer; 1995 Nov; 76(9):1643-54. PubMed ID: 8635070
[TBL] [Abstract][Full Text] [Related]
35. Detection of hematogenic and lymphogenic tumor cell dissemination in patients with medullary thyroid carcinoma by cytokeratin 20 and preprogastrin-releasing peptide RT-PCR.
Weber T; Lacroix J; Wörner S; Weckauf H; Winkler S; Hinz U; Schilling T; Frank-Raue K; Klar E; Knebel Doeberitz Mv Mv
Int J Cancer; 2003 Jan; 103(1):126-31. PubMed ID: 12455065
[TBL] [Abstract][Full Text] [Related]
36. Can We Predict the Lateral Compartment Lymph Node Involvement in RET-Negative Patients with Medullary Thyroid Carcinoma?
Chandeze MM; Noullet S; Faron M; Trésallet C; Godiris-Petit G; Tissier F; Buffet C; Leenhardt L; Chereau N; Menegaux F
Ann Surg Oncol; 2016 Oct; 23(11):3653-3659. PubMed ID: 27271930
[TBL] [Abstract][Full Text] [Related]
37. Repeat mediastinal lymph-node dissection for palliation in advanced medullary thyroid carcinoma.
Machens A; Gimm O; Ukkat J; Sutter T; Dralle H
Langenbecks Arch Surg; 1999 Jun; 384(3):271-6. PubMed ID: 10437616
[TBL] [Abstract][Full Text] [Related]
38. Medullary thyroid cancer: clinico-pathological profile and outcome in a tertiary care center in North India.
Mehrotra PK; Mishra A; Mishra SK; Agarwal G; Agarwal A; Verma AK
World J Surg; 2011 Jun; 35(6):1273-80. PubMed ID: 21479684
[TBL] [Abstract][Full Text] [Related]
39. Prediction of biochemical cure in patients with medullary thyroid cancer.
Machens A; Lorenz K; Dralle H
Br J Surg; 2020 May; 107(6):695-704. PubMed ID: 32108330
[TBL] [Abstract][Full Text] [Related]
40. Progression of medullary thyroid cancer in RET carriers of ATA class A and C mutations.
Machens A; Lorenz K; Dralle H
J Clin Endocrinol Metab; 2014 Feb; 99(2):E286-92. PubMed ID: 24297798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
